Literature DB >> 2255674

Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology.

J J Mongold1, G H Cros, L Vian, A Tep, S Ramanadham, G Siou, J Diaz, J H McNeill, J J Serrano.   

Abstract

This study explored some toxicological aspects of vanadyl sulphate (VOSO4) treatment of rats made diabetic with a single intravenous injection of streptozotocin (60 mg/kg). Administered in drinking water (0.25, 0.5, 0.75 or 1 mg of VOSO4, 5H2O ml) VOSO4 treatment partially or totally corrected some of the alterations associated with the diabetic state (hyperglycaemia, polydipsia, polyphagia, high cholesterol and triglycerides levels) and did not produce any changes in various plasma or blood cell parameters which were not previously altered by diabetes. Measurement of vanadium levels indicated that tissues accumulated vanadium in the following order of concentrations: bone greater than kidney greater than spleen greater than liver greater than lung greater than or equal to muscle greater than blood. Histopathological studies did not reveal any difference in liver, stomach, ileum, spleen, heart and lung from control, non-treated diabetic or VOSO4-treated diabetic animals. Kidney of all non-treated diabetic animals showed an epithelial cellular swelling of distal tubules while only 2 of 6 VOSO4-treated diabetic animals showed this alteration. Cellular degeneration of pancreas B-cells was less marked in VOSO4-treated that in non-treated diabetic animals. The study indicates that VOSO4 may be a potential antidiabetic agent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2255674     DOI: 10.1111/j.1600-0773.1990.tb00812.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  20 in total

1.  Vanadium and diabetes. What about vanadium toxicity?

Authors:  J L Domingo
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

2.  Vanadium and diabetes. What about vanadium toxicity?: A reply.

Authors:  J H McNeill
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

Review 3.  Anti-diabetic and toxic effects of vanadium compounds.

Authors:  A K Srivastava
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 4.  Effects of vanadyl derivatives on animal models of diabetes.

Authors:  G Cros; J J Mongold; J J Serrano; S Ramanadham; J H McNeill
Journal:  Mol Cell Biochem       Date:  1992-02-12       Impact factor: 3.396

Review 5.  New insights into mineralogenic effects of vanadate.

Authors:  Vincent Laizé; Daniel M Tiago; Manuel Aureliano; M Leonor Cancela
Journal:  Cell Mol Life Sci       Date:  2009-09-04       Impact factor: 9.261

Review 6.  Alternative therapies for diabetes and its cardiac complications: role of vanadium.

Authors:  Tod A Clark; Justin F Deniset; Clayton E Heyliger; Grant N Pierce
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

7.  In vivo effects of peroxovanadium compounds in BB rats.

Authors:  J F Yale; C Vigeant; C Nardolillo; Q Chu; J Z Yu; A Shaver; B I Posner
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

8.  Long-term correction of STZ-diabetic rats after short-term i.p. VOSO4 treatment: persistence of insulin secreting capacities assessed by isolated pancreas studies.

Authors:  P Poucheret; R Gross; A Cadène; M Mantéguetti; J J Serrano; G Ribes; G Cros
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 9.  Vanadium and diabetes.

Authors:  P Poucheret; S Verma; M D Grynpas; J H McNeill
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

10.  Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats.

Authors:  M C Cam; R A Pederson; R W Brownsey; J H McNeill
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.